The value of maintaining normokalaemia and enabling RAASi therapy in chronic kidney disease

BACKGROUND: People with chronic kidney disease (CKD) are at an increased risk of developing hyperkalaemia due to their declining kidney function. In addition, these patients are often required to reduce or discontinue guideline-recommended renin-angiotensin-aldosterone system inhibitor (RAASi) thera...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:BMC Nephrol
Hlavní autoři: Evans, Marc, Palaka, Eirini, Furuland, Hans, Bennett, Hayley, Linde, Cecilia, Qin, Lei, McEwan, Phil, Bakhai, Ameet
Médium: Artigo
Jazyk:Inglês
Vydáno: BioMed Central 2019
Témata:
Research Article
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC6357372/
https://ncbi.nlm.nih.gov/pubmed/30704421
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12882-019-1228-y
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky